Rahimi-Levene N - Search Results

1

N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients' daytime blood pressure, and improves inflammatory status.

Doenyas-Barak K, Berman S, Abu-Hamad R, Golik A, Rahimi-Levene N, Efrati S. Doenyas-Barak K, et al. Eur J Clin Pharmacol. 2012 Aug;68(8):1139-46. doi: 10.1007/s00228-012-1235-4. Epub 2012 Feb 25. Eur J Clin Pharmacol. 2012. PMID: 22367427 Clinical Trial.

2

Benign familial microcytic thrombocytosis with autosomal dominant transmission.

Cohen N, Almoznino-Sarafian D, Weissgarten J, Alon I, Zaidenstein R, Dishi V, Rahimi-Levene N, Fried K, Modai D, Golik A. Cohen N, et al. Clin Genet. 1997 Jul;52(1):47-50. doi: 10.1111/j.1399-0004.1997.tb02513.x. Clin Genet. 1997. PMID: 9272712

3

Hemoglobin transfusion trigger in an internal medicine department - A "real world" six year experience.

Rahimi-Levene N, Ziv-Baran T, Peer V, Golik A, Kornberg A, Zeidenstein R, Koren-Michowitz M. Rahimi-Levene N, et al. PLoS One. 2018 Mar 7;13(3):e0193873. doi: 10.1371/journal.pone.0193873. eCollection 2018. PLoS One. 2018. PMID: 29513750 Free PMC article.

4

Lower hemoglobin transfusion trigger is associated with higher mortality in patients hospitalized with pneumonia.

Rahimi-Levene N, Koren-Michowitz M, Zeidenstein R, Peer V, Golik A, Ziv-Baran T. Rahimi-Levene N, et al. Medicine (Baltimore). 2018 Mar;97(12):e0192. doi: 10.1097/MD.0000000000010192. Medicine (Baltimore). 2018. PMID: 29561440 Free PMC article.

5

Hematological Biomarkers, Mortality, Transfusion and Acute Heart Disease.

Rahimi-Levene N, Preisler Y, Koren-Michowitz M, Peer V, Zeidenstein R, Golik A, Ziv-Baran T. Rahimi-Levene N, et al. Am J Med Sci. 2021 Sep;362(3):276-284. doi: 10.1016/j.amjms.2021.04.017. Epub 2021 May 9. Am J Med Sci. 2021. PMID: 33974852

6

Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.

Joffe E, Goldschmidt N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Arad A, Polliack A, Herishanu Y; Israeli CLL Study Group. Joffe E, et al. Eur J Haematol. 2018 Sep;101(3):399-406. doi: 10.1111/ejh.13129. Epub 2018 Aug 3. Eur J Haematol. 2018. PMID: 29949186

7

Rebound thymic enlargement on CT in adults.

Yarom N, Zissin R, Apter S, Hertz M, Rahimi-Levene N, Gayer G. Yarom N, et al. Int J Clin Pract. 2007 Apr;61(4):562-8. doi: 10.1111/j.1742-1241.2006.00950.x. Epub 2007 Jan 29. Int J Clin Pract. 2007. PMID: 17263694

8

Protein Z levels and central retinal vein or artery occlusion.

Koren-Michowitz M, Eting E, Rahimi-Levene N, Garach-Jehoshua O, Volcheck Y, Kornberg A. Koren-Michowitz M, et al. Eur J Haematol. 2005 Nov;75(5):401-5. doi: 10.1111/j.1600-0609.2005.00529.x. Eur J Haematol. 2005. PMID: 16191090

9

The emperor and the blood center.

Rahimi-Levene N, Levene D, Sandler SG. Rahimi-Levene N, et al. Transfusion. 2019 Dec;59(12):3559. doi: 10.1111/trf.15498. Epub 2019 Sep 5. Transfusion. 2019. PMID: 31487053 No abstract available.

10

A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain.

Tadmor T, Braester A, Najib D, Aviv A, Herishanu Y, Yuklea M, Shvidel L, Rahimi-Levene N, Ruchlemer R, Arad A, Fogl C, Henig C, Barak M, Magal L, Polliack A, Townsend K; Israeli CLL study group. Tadmor T, et al. Eur J Haematol. 2019 Oct;103(4):335-341. doi: 10.1111/ejh.13288. Epub 2019 Jul 26. Eur J Haematol. 2019. PMID: 31278876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page